Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.

 

 

2017

Evotec Enters into Research Collaboration with CRTD to Discover Novel Therapies for Retinal Diseases
Nerina Coppini, 13 December 2017

COLLABORATION HIGHLIGHTS EVT INNOVATE’S BUSINESS MODEL TO ACCESS LEADING ACADEMIC EXPERTISE CRTD’S NEXT GENERATION STEM CELL MODELLING WILL ACCELERATE EVOTEC’S ABILITY TO DISCOVER NEW RETINAL DISEASE DRUGS Dresden and Hamburg, Germany, 13 December 2017:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it...

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact
Nerina Coppini, 11 December 2017

THE £ 13 M DRUG DISCOVERY PARTNERSHIP BETWEEN OXFORD UNIVERSITY, OXFORD SCIENCES INNOVATION AND EVOTEC SUPPORTED 12 NEW PROJECTS IN FIRST YEAR OF OPERATION Hamburg, Germany, 11 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the £ 13 m drug discovery partnership between Oxford...

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim
Nerina Coppini, 1 December 2017

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of € 2.00 m to Evotec. The milestone was for...

 

 

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308